JP7821168B2 - 感染を防止するための組成物 - Google Patents

感染を防止するための組成物

Info

Publication number
JP7821168B2
JP7821168B2 JP2023515621A JP2023515621A JP7821168B2 JP 7821168 B2 JP7821168 B2 JP 7821168B2 JP 2023515621 A JP2023515621 A JP 2023515621A JP 2023515621 A JP2023515621 A JP 2023515621A JP 7821168 B2 JP7821168 B2 JP 7821168B2
Authority
JP
Japan
Prior art keywords
composition
sprayable aqueous
aqueous intranasal
intranasal composition
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539940A5 (https=
JP2023539940A (ja
Inventor
トーマス マイヤー，
ファビオ フェイス，
Original Assignee
アルタミラ メディカ， アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルタミラ メディカ， アーゲー filed Critical アルタミラ メディカ， アーゲー
Publication of JP2023539940A publication Critical patent/JP2023539940A/ja
Publication of JP2023539940A5 publication Critical patent/JP2023539940A5/ja
Application granted granted Critical
Publication of JP7821168B2 publication Critical patent/JP7821168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023515621A 2020-09-08 2021-09-03 感染を防止するための組成物 Active JP7821168B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063075590P 2020-09-08 2020-09-08
US63/075,590 2020-09-08
US202063119237P 2020-11-30 2020-11-30
US63/119,237 2020-11-30
US202163173816P 2021-04-12 2021-04-12
US63/173,816 2021-04-12
US202163230191P 2021-08-06 2021-08-06
US63/230,191 2021-08-06
PCT/EP2021/074417 WO2022053412A1 (en) 2020-09-08 2021-09-03 Compositions for preventing infection

Publications (3)

Publication Number Publication Date
JP2023539940A JP2023539940A (ja) 2023-09-20
JP2023539940A5 JP2023539940A5 (https=) 2024-09-11
JP7821168B2 true JP7821168B2 (ja) 2026-02-26

Family

ID=77864552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515621A Active JP7821168B2 (ja) 2020-09-08 2021-09-03 感染を防止するための組成物

Country Status (7)

Country Link
US (2) US12280142B2 (https=)
EP (1) EP4210670A1 (https=)
JP (1) JP7821168B2 (https=)
AU (1) AU2021338957A1 (https=)
CA (1) CA3174314A1 (https=)
TW (1) TW202227104A (https=)
WO (1) WO2022053412A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202227104A (zh) 2020-09-08 2022-07-16 瑞士商艾爾塔米拉醫療有限公司 預防感染之組合物
US20260041706A1 (en) * 2022-08-04 2026-02-12 The Brigham And Women's Hospital, Inc. Mucus membrane formulations and uses thereof
WO2026010400A1 (ko) * 2024-07-03 2026-01-08 (주)시지바이오 스프레이형 점착성 점막 창상피복재

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031512A1 (en) 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
JP2009102425A (ja) 2006-02-09 2009-05-14 Schering Corp 医薬製剤
JP2017515851A (ja) 2014-05-13 2017-06-15 パラゴン ノルディック エービー 植物油とトリグリセリドおよび／または鉱油とを含み噴霧特性が改善された組成物
JP2018522050A (ja) 2015-08-04 2018-08-09 インキューファーム グループ エスディーエヌ ビーエイチディー 経鼻組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2204A1 (fr) 1989-10-31 1992-11-26 Columbia Lab Inc Composition et methode d'humidification de tissus
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
WO1996039031A1 (en) 1995-06-06 1996-12-12 Kimberly-Clark Worldwide, Inc. Microporous film containing a microbial adsorbent
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US6183766B1 (en) 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
DE10064950A1 (de) 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
MXPA04011584A (es) * 2002-05-23 2005-03-31 Umd Inc Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
EP1374856A1 (en) 2002-06-18 2004-01-02 Impetus AG Oily thixotropic nasal spray
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
KR101437708B1 (ko) 2006-12-05 2014-09-03 마리노메드 바이오테크놀로지 게엠베하 항바이러스 조성물과 이의 이용 방법
HRP20130402T1 (hr) 2007-08-24 2013-06-30 Marinomed Biotechnologie Gmbh Antivirusni pripravak koji sadrži sulfatirani polisaharid: jota-karagenan
WO2011029218A1 (zh) 2009-09-09 2011-03-17 济南康众医药科技开发有限公司 蒙脱石在制备药物中的应用
FR2954707B1 (fr) 2009-12-28 2016-01-08 Diffusion Tech Francaise Sarl Dispositif d'administration d'aerosol par voie buccale a visee rhinopharyngee, nasale ou nasosinusienne
WO2012067932A1 (en) 2010-11-19 2012-05-24 Milestone Scientific, Inc. A novel antimicrobial barrier and methods of use thereof to prevent sexually transmitted disease
US20140051732A1 (en) 2011-04-19 2014-02-20 Arm Pharmaceutical Llc Low-tack surface anti-microbial coating composition and method of application
WO2012145307A1 (en) 2011-04-19 2012-10-26 Brian Sokol Method of inhibiting harmful microorganisms and barrier-forming composition therefor
US10426761B2 (en) 2011-04-19 2019-10-01 Arms Pharmaceutical, Llc Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
KR101474858B1 (ko) 2013-04-26 2014-12-19 리드메디 (주) 무방부제 약제를 위생적으로 보관하기 위한 필터부재를 갖는 비강 스프레이 장치
US10398465B2 (en) 2014-04-29 2019-09-03 Misonix Incorporated Ultrasonic surgical instrument assembly, related accessory, and associated surgical method
TW202227104A (zh) 2020-09-08 2022-07-16 瑞士商艾爾塔米拉醫療有限公司 預防感染之組合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031512A1 (en) 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
JP2009102425A (ja) 2006-02-09 2009-05-14 Schering Corp 医薬製剤
JP2017515851A (ja) 2014-05-13 2017-06-15 パラゴン ノルディック エービー 植物油とトリグリセリドおよび／または鉱油とを含み噴霧特性が改善された組成物
JP2018522050A (ja) 2015-08-04 2018-08-09 インキューファーム グループ エスディーエヌ ビーエイチディー 経鼻組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nanoscale Research Letters，2020年，Vol.15，Article ID 173
The Clinical Respiratory Journal，2013年11月27日，Vol.8, No.4，p.382-390

Also Published As

Publication number Publication date
US12280142B2 (en) 2025-04-22
US20220071893A1 (en) 2022-03-10
AU2021338957A1 (en) 2023-05-25
US20260007596A1 (en) 2026-01-08
AU2021338957A9 (en) 2024-08-08
CA3174314A1 (en) 2022-03-17
WO2022053412A1 (en) 2022-03-17
TW202227104A (zh) 2022-07-16
JP2023539940A (ja) 2023-09-20
EP4210670A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US20260007596A1 (en) Compositions for preventing infection
ES2834985T3 (es) Composición que contiene cineol para administración nasal
US9844580B2 (en) Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
JP5604395B2 (ja) マイクロエマルジョンおよび気道疾患を防ぐためのその使用
KR20060118573A (ko) 항바이러스성 약제학적 조성물
JP2014501779A (ja) ベポタスチン組成物
ES2171590T7 (es) Preparación farmacéutica para el tratamiento de rinitis agudas que contiene un simpaticomimético y pantotenol y/o ácido pantoténico
WO2017212422A1 (en) Topical compositions comprising carbomer for the treatment and prevention of viral infections and allergic conditions
CN106659734A (zh) 用于经鼻施用的含硅油制剂
EP2488205A1 (en) Recombinant human cc10 protein for treatment of influenza
JP2026042058A (ja) 組成物およびその用途
JP2017522330A (ja) ポビドンヨードを使用した感冒の治療および予防
CN107847433A (zh) 鼻用组合物
WO2021202332A1 (en) Aqueous formulations containing povidone iodine for effective treatment and prevention of virus infections
CN117083057A (zh) 用于预防感染的组合物
US20230218557A1 (en) A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections
US20240165191A1 (en) Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
JP2012193159A (ja) 鼻用スプレー
Mohammad et al. Development and Physicochemical Characterization of a Poly-Herbal Hydrosol-Based Intranasal Spray for the Management of Rhinosinusitis
US20210330587A1 (en) Oral sanitizer and immune support for viral and bacterial prevention
AU2015204387A1 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
MX2007000927A (en) Methods and compositions for inhibiting, destroying, and/or inactivating viruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821168

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150